Weight and plasma biochemistry.

<div><p>Secondary hyperparathyroidism (sHPT) is a significant clinical complication of CKD leading to bone abnormalities and cardiovascular disease. Current treatment based on activating the parathyroid calcium-sensing receptor (CaSR) using calcimimetics such as Cinacalcet, aims to decre...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Søren Egstrand (10906087) (author)
مؤلفون آخرون:	Maria Lerche Mace (4740072) (author), Marya Morevati (5593805) (author), Lars Henning Engelholm (20513519) (author), Jesper Skovhus Thomsen (9466715) (author), Annemarie Brüel (9544646) (author), Klaus Olgaard (4740075) (author), Ewa Lewin (4740081) (author)
منشور في:	2025
الموضوعات:	Medicine Cell Biology Neuroscience Physiology Pharmacology Biological Sciences not elsewhere classified Chemical Sciences not elsewhere classified transcriptomic analysis showed sup >+</ sup increased adaptive response current treatment based untreated uremic group significant clinical complication hyperplastic parathyroid glands tca cycle </ oxidative phosphorylation </ div >< p 37 %, p 92 ± 0 46 ± 0 cinacalcet drug target significantly reduce ki parathyroid gland proliferation parathyroid cell proliferation without cinacalcet treatment chronotherapy treatment (< 67 index compared parathyroid proliferation cinacalcet treatment cinacalcet (< treatment early significant increase reduced proliferation parathyroid hyperplasia parathyroid calcium cina2 </ cina1 </ >: 0 untreated rats using chronotherapy using calcimimetics upregulated pathways striking effect sensing receptor secondary hyperparathyroidism present study possible benefit mitotic activity markedly impacted inhibitory effect genes involved energy metabolism ckd leading cells compared cardiovascular disease bone abnormalities active phase >, encoding 09 ). 006 ). 001 ). 0001 ).
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

كن أول من يترك تعليقا!

Weight and plasma biochemistry.

مواد مشابهة